Stay updated with breaking news from These Patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
There are many different types of kidney cancer, and they can manifest with a few small metastases or many large ones. Today, though, every patient receives the
As awareness of vascular anomalies grows and research on effective treatments continues, this natural offshoot of hematology and oncology offers a fertile area for career development.
Bentracimab significantly restored platelet function, compared with placebo, in a phase 2b study of older volunteers treated with ticagrelor and aspirin.
KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From ...
This Is the First Anti-PD-1 Combination Approved as First-Line Treatment for These Patients Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose ...